Paradromics Connexus BCI: First Human Implant, 1,684-Channel Specs, and the Race to Restore Speech

The race to build a brain-computer interface that can restore speech to people who have lost the ability to speak has a new front-runner. Austin-based Paradromics has completed its first human implant of the Connexus BCI, secured FDA approval to test speech restoration, and is now enrolling patients in a clinical trial. With 1,684 recording channels — the most of any fully implantable system — the company is betting that higher data bandwidth is the key to unlocking natural, real-time communication for people with paralysis or conditions like ALS.

First Human Implant: A Milestone in the BCI Race

Paradromics achieved its most significant recent milestone in June 2025, when it announced the successful implantation of its Connexus brain-computer interface into a human patient for the first time . The procedure took place on May 14, 2025 at the University of Michigan, led by Dr. Matthew Willsey alongside Dr. Oren Sagher and a multidisciplinary team. The device was implanted in a patient already undergoing epilepsy resection surgery, allowing the team to test the system's safety and ability to record neural signals in a real surgical setting . The implant remained in place for approximately 20 minutes during the operation before being removed, successfully demonstrating the safety of the implantation procedure .

Device Specifications: 1,684 Channels in a Dime-Sized Package

The Connexus system is a fully implantable, wireless intracortical BCI designed to record from individual neurons. Its key specifications include:

• Electrode count: 1,684 recording channels across four cortical modules
• Each module: 421 microwire electrodes, approximately 1.55 mm long and less than 40 microns in diameter, made of platinum-iridium
• Size: A metallic disk smaller than a dime
• Data transmission: Wireless through the skin to an external processor via a secure near-infrared optical link at up to 100 Mbit/s

CEO Matt Angle has stated the system aims to enable communication at speeds of up to 60 words per minute, enough for meaningful conversation . The company also reports that the Connexus BCI achieved an information transfer rate of over 200 bits per second on the SONIC benchmark in preclinical testing — more than 20 times faster than the initial reported performance of other intracortical systems .

Regulatory Milestones: FDA Breakthrough Designation and Trial Approval

Paradromics has accumulated a strong regulatory track record:

• May 2023: FDA granted Breakthrough Device Designation to the Connexus Direct Data Interface
• November 2025: FDA approved an Investigational Device Exemption (IDE) for the Connect-One Early Feasibility Study
• June 2026: Paradromics was accepted into the FDA's Total Product Life Cycle Advisory Program (TAP), a program exclusive to breakthrough-designated devices designed to accelerate the path to market

Paradromics became the first company cleared by the FDA to test speech restoration using a fully implantable BCI . The Connexus BCI has received two Breakthrough Device Designations: one for speech restoration and another for helping patients with motor impairment .

How Paradromics Stacks Up Against Neuralink and Synchron

The three leading BCI companies take very different technical approaches. Here is a direct comparison:

Aspect	Paradromics Connexus	Neuralink N1	Synchron Stentrode
Approach	Fully invasive intracortical	Fully invasive intracortical	Minimally invasive endovascular
Channels	1,684	1,024	~16
Primary target	Speech restoration	Cursor/device control	Texting & digital tasks
Human patients	1+ (enrolling)	12+	~10+
Regulatory stage	IDE (Early Feasibility Study)	IDE	IDE, advancing toward PMA

Paradromics claims the highest channel count among fully implantable BCIs at 1,684 channels . It is the only company specifically approved to test speech restoration with a fully implanted system . The company also argues its platinum-iridium electrode design offers better long-term biocompatibility than Neuralink's polymer threads, with an expected lifespan exceeding a decade . Synchron leads on safety profile (no open-brain surgery required, delivered via catheter through the jugular vein) and is further along in regulatory pathway toward premarket approval (PMA) .

The Connect-One Clinical Study: Goals and Timeline

The Connect-One Early Feasibility Study (EFS) is Paradromics' first human clinical trial . Key details:

• Goal: Evaluate the long-term safety and efficacy of the Connexus BCI for restoring speech and enabling computer control in people with severe motor impairment
• Target population: Individuals with paralysis or neurological conditions who have lost the ability to speak — conditions such as ALS, brainstem stroke, or spinal cord injury
• Enrollment: Began recruiting patients in Q1 2026; open at the University of Michigan and Massachusetts General Hospital, with UC Davis expected to join
• Initial participants: The study will initially enroll two participants

The Bigger Picture: Why Channel Count Matters for Speech

Speech is one of the most complex motor functions the human body performs. Decoding it in real time requires capturing signals from many individual neurons simultaneously — a task that benefits directly from higher channel counts. Paradromics' 1,684 channels exceed both Neuralink's 1,024 and Synchron's 16 by a wide margin, giving it the potential to decode more nuanced neural signatures associated with speech production.

However, higher channel count comes with trade-offs. Fully invasive intracortical surgery carries greater risk than Synchron's endovascular approach, which requires only a catheter inserted through a vein in the neck. Neuralink uses a robotic surgical system to thread its flexible electrodes into the brain, while Paradromics' rigid microwires are implanted directly. The relative safety and long-term performance of each approach will only become clear as clinical data accumulates.

What Comes Next

With its first human implant completed, FDA trial approval secured, and enrollment underway, Paradromics has positioned itself as a serious contender in the BCI space. The Connect-One study will provide the first rigorous data on whether its high-channel-count approach can deliver on the promise of restoring natural, real-time speech. If successful, the Connexus BCI could offer a new communication pathway for the hundreds of thousands of people worldwide who have lost the ability to speak due to paralysis or neurodegenerative disease.